Vulnerable Covid patients to get ready-to-use antibodies

Vulnerable Covid patients to get ready-to-use antibodies

People get vaccinated against Covid-19 at the Bang Sue Central Vaccination Center in Bangkok last month. (Photo: Apichart Jinakul)
People get vaccinated against Covid-19 at the Bang Sue Central Vaccination Center in Bangkok last month. (Photo: Apichart Jinakul)

The Public Health Ministry plans to treat Covid-19 patients at risk of complications with long-acting antibodies (LAAB), according to the Department of Disease Control.

LAAB are now administered as pre-infection protection.

Dr Sophon Iamsirithaworn, deputy director-general of the department, said on Wednesday that studies showed that LAAB made by Evusheld could be used to effectively treat Covid-19 patients. Japan and Europe have already approved their use for vulnerable Covid-19 patients.

He said that Thailand would follow suit, in addition to using it to protect vulnerable groups of people who had not contracted Covid-19.

Lancet Respiratory Medicine published findings from the Phase 3 TACKLE trial project with 910 Covid-19 outpatients with mild and moderate symptoms at 95 hospitals in the United States, Europe and Japan.

The trial project showed that the use of Evusheld LAAB can reduce the incidence of severe illness and death by 50% when administered within seven days after symptoms first appear. The reduction will be 67% and 88% for administration within five and three days respectively after symptoms arise, Dr Sophon said.

A study of 1,417 inpatients who had shown symptoms for no longer than 12 days at 81 hospitals in the US, Europe, Uganda and Singapore found that Evusheld cut the fatality rate by 30%.

"This shows the effectiveness of Evusheld's ready-to-use antibodies in the treatment of Covid-19 patients," Dr Sophon said.

On Aug 30 Japan's Ministry of Health, Labour and Welfare approved the use of Evusheld to treat Covid-19 patients aged 12 years and over who were at risk of developing severe symptoms. On Tuesday the European Medicines Agency agreed to use Evusheld for newly-infected Covid-19 patients at high risk, he said.

According to Dr Sophon, the Public Health Ministry procured Evusheld's LAAB for people with low antibodies and those who cannot develop antibodies after vaccination. LAAB is used to protect people before they are exposed to Covid-19.

"More than 3,400 people have been injected with LAAB. It can tackle the original strain and many variants of the Covid-19 virus," he said.

The inoculation initially targets those dependent on dialysis and patients who have undergone organ and bone marrow transplantation.

The protection with LAAB will expand to other groups of people, including cancer patients who are receiving chemotherapy and radiotherapy, patients with low antibodies and patients who have immunosuppressants after receiving transplants and joint treatment, Dr Sophon said.

Do you like the content of this article?

Poland burst Saudi bubble in Qatar

AL-RAYYAN, Qatar: Robert Lewandowski scored his first ever World Cup goal as Poland brought Saudi Arabia back down to earth with a bump on Saturday with an 2-0 Group C victory that rejuvenated their tournament campaign.

26 Nov 2022

Taiwan president's party humbled in local polls

TAIPEI: Taiwan President Tsai Ing-wen’s ruling party suffered a major defeat in Saturday’s local elections, which are seen as a prelude to the island’s 2024 presidential and legislative elections.

26 Nov 2022

Four held after 1.2m speed pills seized

Four members of a suspected drug network in the South have been arrested in Nakhon Si Thammarat with 1.2 million speed pills seized, while another 300,000 speed pills were found abandoned by a smuggler in Fang district of Chiang Mai, authorities said on Saturday.

26 Nov 2022